Karyopharm Therapeutics Inc.
KPTI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $145 | $146 | $157 | $210 |
| % Growth | -0.5% | -7% | -25.1% | – |
| Cost of Goods Sold | $6 | $5 | $5 | $3 |
| Gross Profit | $139 | $141 | $152 | $206 |
| % Margin | 95.9% | 96.6% | 96.7% | 98.4% |
| R&D Expenses | $143 | $139 | $149 | $161 |
| G&A Expenses | $115 | $132 | $145 | $144 |
| SG&A Expenses | $115 | $132 | $145 | $144 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $259 | $271 | $294 | $305 |
| Operating Income | -$119 | -$130 | -$142 | -$98 |
| % Margin | -82.2% | -88.7% | -90.5% | -46.8% |
| Other Income/Exp. Net | $43 | -$13 | -$23 | -$26 |
| Pre-Tax Income | -$76 | -$143 | -$165 | -$124 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$76 | -$143 | -$165 | -$124 |
| % Margin | -52.6% | -98% | -105.2% | -59.1% |
| EPS | -9.41 | -18.79 | -30.28 | -24.75 |
| % Growth | 49.9% | 37.9% | -22.3% | – |
| EPS Diluted | -9.41 | -18.79 | -30.28 | -24.75 |
| Weighted Avg Shares Out | 8 | 8 | 5 | 5 |
| Weighted Avg Shares Out Dil | 8 | 8 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $11 | $2 | $1 |
| Interest Expense | $37 | $24 | $25 | $26 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$39 | -$118 | -$139 | -$97 |
| % Margin | -26.6% | -81.1% | -88.7% | -46.2% |